Back to results
US 2026/0076970 A1Published application
Cancer treatment using mtdp inhibitors and plk1 inhibitors
AssigneeCardiff Oncology, Inc.
InventorsMaya Ridinger, Tod Smeal, Mark Erlander
Life of this patent
Estimating the term…
Abstract
Provided include methods, compositions and kits for treating cancer in a subject. The method can comprise administrating an MTDP inhibitor (for example, paclitaxel) and a PLK1 inhibitor (for example, onvansertib) to the subject in a manner sufficient to inhibit or reduce progression of the cancer.
Claims75
A method of treating cancer, the method comprising:
- administrating a microtubule depolymerization (MTDP) inhibitor and a Polo-like kinase 1 (PLK1) inhibitor to a subject with cancer, thereby inhibiting or reducing progression of the cancer in the subject.
A method of sensitizing cancer cells to a microtubule depolymerization (MTDP) inhibitor, the method comprising:
- contacting cancer cells with a composition comprising a Polo-like kinase 1 (PLK1) inhibitor, thereby sensitizing the cancer cells to the MTDP inhibitor;
- optionally wherein the PLK1 inhibitor is onvansertib and/or MTDP inhibitor is paclitaxel.
A kit, comprising:
- a polo-like kinase 1 (PLK1) inhibitor;
- and
- a manual providing instructions for co-administrating the PLK1 inhibitor with a microtubule depolymerization (MTDP) inhibitor to a subject in need thereof for treating cancer.
Dependencies are inferred from the claim text.